Skip to main content
logo
Becton, Dickinson and Company (BDX)
NYSE: BDX · Real-Time Price · USD
163.88
-0.53 (-0.32%)
At close: Mar 10, 2026, 4:00 PM EDT
163.88
0.00 (0.00%)
After-hours: Mar 10, 2026, 7:00 PM EDT

Revenue Breakdown

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 Sep '19 Sep '18 Sep '17 Sep '16 Sep '15 Sep '14 Sep '13 Sep '12
Medication Delivery Solutions Revenue
4.58B4.58B4.43B
Medication Delivery Solutions Revenue Growth
0.09%3.30%3.17%
Medication Management Solutions Revenue
3.51B3.47B3.30B
Medication Management Solutions Revenue Growth
0.98%5.37%10.64%
Pharmaceutical Systems Revenue
2.34B2.32B2.27B
Pharmaceutical Systems Revenue Growth
0.47%2.24%1.97%
Advanced Patient Monitoring Revenue
1.11B1.08B74.00M
Advanced Patient Monitoring Revenue Growth
2.40%1362.16%-
Specimen Management Revenue
1.88B1.87B1.83B
Specimen Management Revenue Growth
0.32%2.07%-
Diagnostic Solusions Revenue
1.80B1.84B1.85B
Diagnostic Solusions Revenue Growth
-1.96%-0.43%-
Integrated Diagnostic Solutions Revenue
3.68B3.71B3.68B
Integrated Diagnostic Solutions Revenue Growth
-0.81%0.81%1.52%
Biosciences Revenue
1.42B1.46B1.51B
Biosciences Revenue Growth
-2.33%-3.57%0.20%
Surgery Revenue
1.60B1.57B1.49B
Surgery Revenue Growth
1.53%5.36%-0.33%
Peripheral Intervention Revenue
2.01B2.00B1.93B
Peripheral Intervention Revenue Growth
0.60%3.26%3.65%
Urology and Critical Care Revenue
1.69B1.65B1.55B
Urology and Critical Care Revenue Growth
2.24%6.11%13.10%
Revenue (Other)
-3.68B-3.71B-3.74B
Revenue (Total)
21.92B21.84B20.18B
Revenue (Total) Growth
0.39%8.24%4.16%

Revenue by Geography

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 Sep '19 Sep '18 Sep '17 Sep '16 Sep '15 Sep '14 Sep '13 Sep '12
United States Revenue
12.87B12.79B11.66B
United States Revenue Growth
0.62%9.66%4.95%
International Revenue
9.05B9.05B8.52B
International Revenue Growth
0.04%6.27%3.11%
Revenue (Other)
2.00M1.00M-
Revenue (Total)
21.92B21.84B20.18B
Revenue (Total) Growth
0.39%8.24%4.16%

Revenue Breakdown 3

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 Sep '19 Sep '18 Sep '17 Sep '16 Sep '15 Sep '14 Sep '13 Sep '12
Medical Revenue
-11.46B10.07B
Medical Revenue Growth
-13.72%6.02%
Life Sciences Revenue (Pre-FY2026 Reporting)
-5.17B5.19B
Life Sciences Revenue (Pre-FY2026 Reporting) Growth
--0.46%1.13%
Interventional Revenue (Pre-FY2026 Reporting)
-5.22B4.98B
Interventional Revenue (Pre-FY2026 Reporting) Growth
-4.76%5.15%
Revenue (Total)
21.92B21.84B20.18B
Revenue (Total) Growth
0.39%8.24%4.16%

EBIT 2

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 Sep '19 Sep '18 Sep '17 Sep '16 Sep '15 Sep '14 Sep '13 Sep '12
Medical Segment Operating Income
--2.74B
Medical Segment Operating Income Growth
--39.40%
Life Sciences Segment Operating Income (Pre-FY2026 Reporting)
--1.60B
Life Sciences Segment Operating Income (Pre-FY2026 Reporting) Growth
--0.63%
Interventional Segment Operating Income (Pre-FY2026 Reporting)
--1.42B
Interventional Segment Operating Income (Pre-FY2026 Reporting) Growth
--16.68%
Operating Income (Total)
2.68B2.58B2.40B
Operating Income (Total) Growth
3.80%7.59%13.55%
Updated Dec 31, 2025. Data Source: Fiscal.ai.